These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 2524732)
21. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. Sykes M; Sheard M; Sachs DH J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804 [TBL] [Abstract][Full Text] [Related]
22. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S Clin Transpl; 1996; ():281-90. PubMed ID: 9286578 [TBL] [Abstract][Full Text] [Related]
23. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
24. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion. Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of pretransplant donor anti-recipient cytotoxic and helper T lymphocyte responses as correlates of acute graft-vs.-host disease and survival after unrelated marrow transplantation. Pei J; Martin PJ; Longton G; Masewicz S; Mickelson E; Petersdorf E; Anasetti C; Hansen J Biol Blood Marrow Transplant; 1997 Aug; 3(3):142-9. PubMed ID: 9310191 [TBL] [Abstract][Full Text] [Related]
26. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient]. Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503 [TBL] [Abstract][Full Text] [Related]
27. Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation. van Dijk AM; Kessler FL; Verdonck LF; Stadhouders-Keet SA; van Lier RA; de Gast GC; Otten HG Br J Haematol; 2000 Dec; 111(3):791-6. PubMed ID: 11122139 [TBL] [Abstract][Full Text] [Related]
28. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
29. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434 [TBL] [Abstract][Full Text] [Related]
30. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307 [TBL] [Abstract][Full Text] [Related]
31. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937 [TBL] [Abstract][Full Text] [Related]
32. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473 [TBL] [Abstract][Full Text] [Related]
33. An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Sviland L; Dickinson AM; Carey PJ; Pearson AD; Proctor SJ Bone Marrow Transplant; 1990 Feb; 5(2):105-9. PubMed ID: 1968774 [TBL] [Abstract][Full Text] [Related]
34. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Soiffer RJ; Ritz J Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262 [TBL] [Abstract][Full Text] [Related]
35. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF. Chen HR; Ji SQ; Wang HX; Yan HM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770 [TBL] [Abstract][Full Text] [Related]
36. Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. Lum LG; Noges JE; Beatty P; Martin PJ; Deeg J; Doney KC; Loughran T; Sullivan KM; Witherspoon RP; Thomas ED Bone Marrow Transplant; 1988 Sep; 3(5):399-406. PubMed ID: 3056548 [TBL] [Abstract][Full Text] [Related]
37. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens. Leshem B; Tsuberi BZ; Lebendiker Z; Anafi-Ayalon M; Shalit M; Weiss L; Slavin S; Kedar E Transplantation; 1987 Jun; 43(6):814-7. PubMed ID: 2954282 [TBL] [Abstract][Full Text] [Related]
38. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow. Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073 [TBL] [Abstract][Full Text] [Related]
39. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666 [TBL] [Abstract][Full Text] [Related]
40. Allogeneic bone marrow transplantation: state of the art and future directions. Goldman JM Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():133-4. PubMed ID: 2653489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]